Cardiovascular Agents Could Be The Heart Of 2015’s New Drug Class
Executive Summary
Expect upheavals in the cardiovascular disease landscape in 2015 as FDA considers new drugs that could significantly change the management of chronic heart failure while payers brace for the introduction of PCSK9 inhibitors for hypercholesterolemia.
You may also be interested in...
Novartis Execs Highlight Cosentyx, LCZ696 As Key 2015 Launches
The swapping of product portfolios with other companies remains on track at Switzerland’s big pharma Novartis, despite a seven-percentage-point sales erosion due to emerging generic competition during 2014, and more recent currency turmoil in its home country.
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.